The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ALEXION PHARMACEUTICALS INC | COM | 015351109 | 91,285 | 797,740 | SH | SOLE | 797,740 | 0 | 0 | ||
| ALKERMES PLC | SHS | G01767105 | 129,660 | 7,825,000 | SH | SOLE | 7,825,000 | 0 | 0 | ||
| BioCryst Pharmaceuticals Inc | COM | 09058V103 | 16,697 | 4,861,000 | SH | SOLE | 4,861,000 | 0 | 0 | ||
| BIOGEN INC | COM | 09062X103 | 182,406 | 643,000 | SH | SOLE | 643,000 | 0 | 0 | ||
| INNOVIVA INC | COM | 45781M101 | 67,026 | 6,414,000 | SH | SOLE | 6,414,000 | 0 | 0 | ||
| INTERCEPT PHARMACEUTICALS INC | COM | 45845P108 | 49,793 | 1,201,000 | SH | SOLE | 1,201,000 | 0 | 0 | ||
| IRONWOOD PHARMACEUTICALS INC | COM CL A | 46333X108 | 126,289 | 14,040,000 | SH | SOLE | 14,040,000 | 0 | 0 | ||
| JAZZ PHARMACEUTICALS PLC | SHS USD | G50871105 | 132,337 | 928,100 | SH | SOLE | 928,100 | 0 | 0 | ||
| MERSANA THERAPEUTICS INC | COM | 59045L106 | 52,824 | 2,837,000 | SH | SOLE | 2,837,000 | 0 | 0 | ||
| MIRATI THERAPEUTICS INC | COM | 60468T105 | 166 | 1,000 | SH | SOLE | 1,000 | 0 | 0 | ||
| REGULUS THERAPEUTICS INC | COM NEW | 75915K200 | 951 | 1,851,851 | SH | SOLE | 1,851,851 | 0 | 0 | ||